Stifel Nicolaus & Co. Vice President Brian Klein is currently recommending Medivation Inc (MDVN) to investors. He says he expects the company to be able to address a larger patient population with its prostate cancer drug.
“They have one approved product, it’s called XTANDI, and it’s for the treatment of prostate cancer,” Klein says. “In this case, or currently I should say, it’s approved in patients after they have received chemotherapy. And we’re hopeful that the drug will be approved shortly for patients prior to chemotherapy as well, and that’s based on some clinical trials that were previously conducted and reported already which showed a survival benefit if you were treated with this product ahead of chemotherapy.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Klein says the patient population of men who get prostate cancer is quite large. As such, he believes the data is compelling for Medivation.
“Certainly it’s been tested in a number of patients,” Klein says. “It’s already approved, it’s already selling quite well, and we think that the label expansion, which we are forecasting will occur in mid-September, will allow them to address an even larger patient population and help that disease.”
Margin Expansion Likely for Brown & Brown, Inc. (BRO) in Q2
June 16, 2014
WellPoint (WLP), UnitedHealth (UNH) and Humana (HUM) Expected to Benefit from Upcoming Health Care Expansion If Democrats Win
October 25, 2012
Interxion Holding NV (INXN) to Benefit from 2012 Capacity Growth, Sees Margin Expansion Potential
May 13, 2013
SunEdison Inc (SUNE) Likely to Announce Yield Co. Structures
March 03, 2014
Janus Capital Group Inc (JNS) Shares Likely To Go Up This Year
April 03, 2014
